Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR in Haploidentical Stem Cell Transplant
NCT00967343Phase 3Terminated
- Sponsor
- Kiadis Pharma
- Start
- Aug 2009
- Primary completion
- Feb 2012
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 7
01
Overview
A Phase 3 trial of ATIR101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), sponsored by Kiadis Pharma. Started Aug 2009; status: terminated.
02
Drugs
ATIR101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00967343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967343.